Guardian Wealth Advisors LLC Purchases 231 Shares of Johnson & Johnson (NYSE:JNJ)

Guardian Wealth Advisors LLC increased its stake in Johnson & Johnson (NYSE:JNJ) by 3.9% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 6,130 shares of the company’s stock after purchasing an additional 231 shares during the period. Johnson & Johnson makes up 0.7% of Guardian Wealth Advisors LLC’s holdings, making the stock its 19th biggest holding. Guardian Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $1,017,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of JNJ. Norges Bank bought a new position in Johnson & Johnson in the fourth quarter valued at about $4,390,037,000. GAMMA Investing LLC raised its position in shares of Johnson & Johnson by 24,450.4% during the first quarter. GAMMA Investing LLC now owns 7,215,367 shares of the company’s stock worth $1,196,596,000 after purchasing an additional 7,185,977 shares during the period. Bank of New York Mellon Corp grew its holdings in Johnson & Johnson by 26.4% during the first quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company’s stock worth $3,844,580,000 after buying an additional 4,842,582 shares in the last quarter. Janus Henderson Group PLC grew its holdings in Johnson & Johnson by 134.5% during the fourth quarter. Janus Henderson Group PLC now owns 7,948,508 shares of the company’s stock worth $1,149,536,000 after buying an additional 4,559,147 shares in the last quarter. Finally, Northern Trust Corp grew its holdings in Johnson & Johnson by 12.3% during the fourth quarter. Northern Trust Corp now owns 30,813,175 shares of the company’s stock worth $4,456,201,000 after buying an additional 3,363,235 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on JNJ. Leerink Partners downgraded Johnson & Johnson from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $169.00 to $153.00 in a research note on Tuesday, May 13th. Raymond James Financial cut their price target on Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating for the company in a research note on Monday, April 14th. The Goldman Sachs Group raised Johnson & Johnson from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $157.00 to $172.00 in a report on Wednesday, April 9th. Bank of America lowered their price target on Johnson & Johnson from $171.00 to $159.00 and set a “neutral” rating on the stock in a report on Thursday, April 10th. Finally, Barclays reduced their price objective on Johnson & Johnson from $166.00 to $165.00 and set an “equal weight” rating on the stock in a research report on Thursday, April 17th. Eleven analysts have rated the stock with a hold rating, seven have issued a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $171.00.

Johnson & Johnson Price Performance

Shares of JNJ stock opened at $164.78 on Thursday. The firm has a market cap of $396.47 billion, a P/E ratio of 18.33, a P/E/G ratio of 2.12 and a beta of 0.41. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99. The business’s 50 day moving average price is $153.95 and its 200-day moving average price is $154.71. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating analysts’ consensus estimates of $2.68 by $0.09. The company had revenue of $23.74 billion during the quarter, compared to analysts’ expectations of $22.85 billion. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. The firm’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same quarter last year, the business posted $2.82 EPS. On average, equities research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 3.16%. Johnson & Johnson’s payout ratio is 57.84%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.